Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly ...
Lexaria Bioscience Corp. is a healthcare/biotechnology company building next-generation oral (and related) drug-delivery formulations using its proprietary DehydraTECH™ technology. The company’s central value proposition is that DehydraTECH is engineered to improve delivery of bioactive compounds after oral administration—aiming to increase absorption into the bloodstream and to improve clinical and patient-relevant ...Lexaria Bioscience Corp. is a healthcare/biotechnology company building next-generation oral (and related) drug-delivery formulations using its proprietary DehydraTECH™ technology. The company’s central value proposition is that DehydraTECH is engineered to improve delivery of bioactive compounds after oral administration—aiming to increase absorption into the bloodstream and to improve clinical and patient-relevant performance characteristics such as faster onset and more tolerable dosing.
From a product and technology perspective, DehydraTECH is described as a platform that can enhance bioavailability of compounds by multiple folds compared with standard formulations (including reported improvements in contexts such as cannabinoids and nicotine), while also reducing the time to onset from hours to minutes and helping neutralize unpleasant tastes. The platform is also positioned for broader applications beyond earlier use cases, with evaluations involving orally administered antiviral drugs, NSAIDs (non-steroidal anti-inflammatory drugs), PDE5 inhibitors, and other compounds. Additionally, DehydraTECH is described as having the capability to facilitate passage across the blood-brain barrier, which can expand its potential utility for CNS-relevant therapeutic areas.
Operationally, Lexaria operates a licensed in-house formulation development and research laboratory. This internal capability supports formulation development, processing, and ongoing research activities, while the company also pursues out-licensing opportunities for the technology. Intellectual property is a major business pillar: the company maintains a portfolio of granted patents and many pending patent applications globally, which helps protect the platform and can support licensing negotiations and partnered development.
In terms of cost and business economics, like many early-stage or R&D-intensive biotech firms, Lexaria’s model involves investing in formulation development, preclinical/clinical-enabling work, and IP development/maintenance. The company’s public financial metrics (as reflected in the provided dataset snapshot) indicate profitability challenges (negative margins and cash flow measures), which is common for R&D-focused companies that prioritize development and commercialization readiness before scaling revenues.
Key people include CEO Richard C. Christopher, along with leadership roles such as John Docherty (President and Chief Scientific Officer) and Michael Shankman (CFO), reflecting a management structure oriented toward scientific development and corporate/financial stewardship.
Looking forward, Lexaria’s stated and implied goals are to expand the pipeline of drug applications for DehydraTECH, convert technology development into commercial outcomes through out-licensing and partnerships, and continue strengthening its patent estate to defend and monetize its formulation platform. The company is headquartered in Kelowna, British Columbia, Canada, and trades publicly on the NASDAQ Capital Market under the ticker LEXX.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$705923
+52.0%
-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-11.9M
-105.4%
-37.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+99.6%
+0.7%
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-1683.0%
-35.8%
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-1686.0%
-35.1%
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-10.5M
-109.4%
+25.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-1483.9%
-37.7%
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
3.7%
+113.9%
+28.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.32x
-67.7%
-60.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
